JGP Wealth Management LLC Has $15.80 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

JGP Wealth Management LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,862 shares of the medical research company’s stock after acquiring an additional 286 shares during the period. Amgen makes up 2.3% of JGP Wealth Management LLC’s holdings, making the stock its 10th largest position. JGP Wealth Management LLC’s holdings in Amgen were worth $15,801,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Fuller & Thaler Asset Management Inc. increased its stake in Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after purchasing an additional 193 shares in the last quarter. Diversified Trust Co grew its stake in Amgen by 76.8% during the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after acquiring an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC lifted its position in shares of Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after purchasing an additional 117 shares in the last quarter. Platform Technology Partners grew its position in Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares in the last quarter. Finally, Busey Trust CO boosted its stake in shares of Amgen by 1.2% during the 3rd quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock valued at $20,615,000 after buying an additional 894 shares during the period. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Stock Up 0.8 %

Shares of NASDAQ:AMGN traded up $2.03 during midday trading on Monday, reaching $270.90. 3,608,328 shares of the company were exchanged, compared to its average volume of 3,099,191. The firm has a market cap of $145.18 billion, a PE ratio of 21.69, a P/E/G ratio of 2.54 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The stock has a fifty day simple moving average of $293.86 and a two-hundred day simple moving average of $279.74. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.09 earnings per share. As a group, sell-side analysts forecast that Amgen Inc. will post 19.48 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.32%. Amgen’s dividend payout ratio is 72.06%.

Analyst Ratings Changes

Several research analysts have recently commented on AMGN shares. StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Monday, March 11th. Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a report on Wednesday, November 29th. Oppenheimer reissued an “outperform” rating and issued a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. Morgan Stanley lowered their price objective on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. Finally, UBS Group lowered their target price on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.